All In Biotech

Drug Trial Radar · NCT05653219

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First Line Steroid Treatment (VAYHIT2)

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

152

Actual

Start

Feb 2, 2023

Primary completion

Jun 19, 2025

Study completion Apr 8, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with steroids.

Conditions

  • Primary Immune Thrombocytopenia

Interventions

  • IanalumabBiological

    Concentrate for solution for infusion for intravenous use

  • EltrombopagDrug

    Film-coated tablet for oral use

  • PlaceboDrug

    Concentrate for solution for infusion for intravenous use.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time from randomization until treatment failureTime frame: Randomization to until end of study (up to 39 months after randomization of last participant)

Locations

74 sites in 24 countries. Site status is shown where the registry gives one.

  • Yuma Regional Medical Center

    Yuma, Arizona

  • University of Colorado Anschutz

    Aurora, Colorado

  • Endeavor Health

    Evanston, Illinois

  • Boston Medical Center

    Boston, Massachusetts

  • UMASS Memorial Medical Center

    Worcester, Massachusetts

  • Michigan Center of Medical Research

    Farmington Hills, Michigan

  • St Vincent Frontier Cancer Center

    Billings, Montana

  • Hematology Oncology Association of Rockland

    Nyack, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Novartis Investigative Site

    CABA, Argentina

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Yvoir, Namur, Belgium

  • Novartis Investigative Site

    Roeselare, West Vlaanderen, Belgium

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Jinan, China

  • Novartis Investigative Site

    Tianjin, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Wuhan, Hubei, China

  • Novartis Investigative Site

    Binzhou, Shandong, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, China

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Blois, France

  • Novartis Investigative Site

    Le Mans, France

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Dresden, Saxony, Germany

  • Novartis Investigative Site

    Jena, Thuringia, Germany

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, Hungary

  • Novartis Investigative Site

    Rishikesh, Uttarakhand, India

  • Novartis Investigative Site

    Kolkata, West Bengal, India

  • Novartis Investigative Site

    Bologna, BO, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Trieste, TS, Italy

  • Novartis Investigative Site

    Kumamoto, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site

    Osaka, Osaka, Japan

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.